Research and Markets: PharmaPoint Analysis: Multiple Sclerosis – US Drug Forecast and Market Analysis to 2022

DUBLIN--(BUSINESS WIRE)--

Research and Markets (http://www.researchandmarkets.com/research/n5dsmq/pharmapoint) has announced the addition of the "PharmaPoint: Multiple Sclerosis - US Drug Forecast and Market Analysis to 2022" report to their offering.

PharmaPoint: Multiple Sclerosis - US Drug Forecast and Market Analysis to 2022. Multiple sclerosis (MS) is a chronic, inflammatory neurological disorder characterized pathologically by demyelination, axonal transection and neurodegeneration within the central nervous system. With curative therapy still elusive, current disease management is dependent on life-long pharmacotherapy with disease-modifying therapies (DMT). The dominance of first-line injectable DMTs, including the interferon beta (IFN) agents: Bayer's Betaseron/Betaferon (IFN-1b), Biogen's Avonex (IFN-1a) and Merck's Rebif (IFN-1a), and Teva's Copaxone (glatiramer acetate), has been a salient feature of the MS therapeutics market. However, the competitive landscape is undergoing significant change with the emergence of oral therapies, several pipeline products with notable efficacies, and looming generics/biosimilars following the patent expiries of key branded products during the forecast period. In addition, the entry of new companies such as Sanofi/Genzyme and F. Hoffmann-La-Roche/Genentech will challenge the position of the established players in the MS marketplace.

The US is the largest MS market due to the high prevalence of the disease and comparatively high MS drug prices.During the forecast period, the major driver for market growth is an increase in the diagnosis rate following adoption of the revised 2010 McDonald criteria, which greatly reduced the time to diagnosis, and the push by physicians for the earlier initiation of treatment in patients. Other important drivers include the launch of several pipeline DMTs that provide improved efficacy and convenient administration, as well as increased accessibility to treatment due to US healthcare reform, which will both result in higher treatment rates. Furthermore, the launch of novel DMTs that specifically target progressive MS, such as masitinib and siponimod, will also increase treatment uptake by patients with PPMS or SPMS. With several key patent expiries of leading branded products occurring throughout the forecast period, generic erosion will be the biggest barrier to market growth.

Scope

- Overview of the Multiple Sclerosis including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape.

- Detailed information on the key drugs in the US including product description, safety and efficacy profiles as well as a SWOT analysis.

- Sales forecast for the top drugs in the US from 2012-2022.

- Analysis of the impact of key events as well the drivers and restraints affecting the US Multiple Sclerosis market.

Key Topics Covered:

Originally posted here:
Research and Markets: PharmaPoint Analysis: Multiple Sclerosis - US Drug Forecast and Market Analysis to 2022